INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm
16 avr. 2024 13h50 HE
|
Schall Law
The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, and Checkpoint and Encourages Investors to Contact the Firm
12 avr. 2024 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, April 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint
12 avr. 2024 10h20 HE
|
Faruqi & Faruqi LLP
NEW YORK, April 12, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Checkpoint Therapeutics, Inc. (“Checkpoint”...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm
10 avr. 2024 15h02 HE
|
Schall Law
The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm
CHECKPOINT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Checkpoint Therapeutics, Inc. and Encourages Investors to Contact the Firm
08 avr. 2024 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against...
EvolveImmune Therapeutics Presents New Preclinical and Translational Data on Novel CD2 Costimulatory T Cell Engager Platform at 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
06 nov. 2023 07h00 HE
|
EvolveImmune
BRANFORD, Conn., Nov. 06, 2023 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome the therapeutic...
EvolveImmune Therapeutics Enters into Strategic Research Collaboration with Kennedy Institute of Rheumatology
14 juin 2023 07h00 HE
|
EvolveImmune
BRANFORD, Conn., June 14, 2023 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome cancer-driven...
EvolveImmune Therapeutics Reports First Results from CRISPR-Cas9 T Cell Exhaustion Screening Platform at American Association for Cancer Research (AACR) Annual Meeting 2023
18 avr. 2023 09h00 HE
|
EvolveImmune
Novel Technology Identified Genes that Promote T Cell Exhaustion, and which are Unique from PD-1/PD-L1 Checkpoint Pathway Engineered CAR-T Cells Lacking Exhaustion-Associated Genes Mediate Improved...
Equillium to Present Translational Preclinical Data Demonstrating Increased Survival and Decreased Disease Severity in Models of Graft-Versus-Host Disease Treated with Itolizumab at the Transplantation & Cellular Therapy Meetings of ASTCT & CIBMTR
29 janv. 2020 16h07 HE
|
Equillium
LA JOLLA, Calif., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium Reports Second Quarter 2019 Financial Results and Recent Highlights
12 août 2019 16h07 HE
|
Equillium
Initiated Phase 1b EQUIP proof-of-concept trial evaluating itolizumab (EQ001) for the treatment of uncontrolled asthma Investigational New Drug (IND) application accepted by FDA for itolizumab for...